[
  {
    "ts": null,
    "headline": "Biotech stocks dip as Trump administration mulls patent fee overhaul",
    "summary": "Investing.com -- Biotech stocks fell across the board Monday afternoon, with the SPDR S&P Biotech ETF (NYSE:XBI) dropping to a low of 1.1% after reports emerged that the Trump administration is considering a major overhaul of the U.S. patent system.",
    "url": "https://finnhub.io/api/news?id=62c4a767d17ea9fa389a30852e09a3357654725d5a485cea652900b5d9b1c91a",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753733633,
      "headline": "Biotech stocks dip as Trump administration mulls patent fee overhaul",
      "id": 136113491,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Investing.com -- Biotech stocks fell across the board Monday afternoon, with the SPDR S&P Biotech ETF (NYSE:XBI) dropping to a low of 1.1% after reports emerged that the Trump administration is considering a major overhaul of the U.S. patent system.",
      "url": "https://finnhub.io/api/news?id=62c4a767d17ea9fa389a30852e09a3357654725d5a485cea652900b5d9b1c91a"
    }
  },
  {
    "ts": null,
    "headline": "Biogen Gears Up to Report Q2 Earnings: Here's What to Expect",
    "summary": "Biogen's Q2 results may show MS drug declines partially offset by gains from newer drugs.",
    "url": "https://finnhub.io/api/news?id=ae60b02c0449d28f4fff96c21b0e1eebd1c463a0d29e887217f207d5b258b2a4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753712640,
      "headline": "Biogen Gears Up to Report Q2 Earnings: Here's What to Expect",
      "id": 136107934,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "Biogen's Q2 results may show MS drug declines partially offset by gains from newer drugs.",
      "url": "https://finnhub.io/api/news?id=ae60b02c0449d28f4fff96c21b0e1eebd1c463a0d29e887217f207d5b258b2a4"
    }
  },
  {
    "ts": null,
    "headline": "BioMarin Pharmaceutical (BMRN) Reports Next Week: Wall Street Expects Earnings Growth",
    "summary": "BioMarin (BMRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
    "url": "https://finnhub.io/api/news?id=6eb26532af4c27d00b0334c5235572d937e7c5eec9835baae2552f5f10afd34f",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1753711208,
      "headline": "BioMarin Pharmaceutical (BMRN) Reports Next Week: Wall Street Expects Earnings Growth",
      "id": 136108927,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "BIIB",
      "source": "Yahoo",
      "summary": "BioMarin (BMRN) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.",
      "url": "https://finnhub.io/api/news?id=6eb26532af4c27d00b0334c5235572d937e7c5eec9835baae2552f5f10afd34f"
    }
  }
]